Selcia and Cantab announce drug discovery collaboration
3 September 2013 | By O2PR LTD
Selcia Limited has entered into a drug discovery collaboration with Cantab Anti-Infectives...
List view / Grid view
News
Simultaneous applications submitted to FDA and EMA for siltuximab for the treatment of MCD, a rare blood disorder
3 September 2013 | By Johnson & Johnson
“We’re proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need”
Subanalysis of Phase III ARISTOTLE trial of Eliquis® (apixaban) demonstrated consistent results versus warfarin in patients with NVAF with or without valvular heart disease
3 September 2013 | By Pfizer
Data show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death...
Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2]
2 September 2013 | By Novartis
New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress[1],[2]...
GSK receives marketing authorisation from the European Commission for Tafinlar™ (dabrafenib)
2 September 2013 | By GlaxoSmithKline
GSK announced that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib)...
Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
2 September 2013 | By Roche
Roche announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission...
Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial at ERS 2013
2 September 2013 | By Boehringer Ingelheim
Results from TIOSPIR™ will be presented for the first time at the Annual Congress of the European Respiratory Society...
ONGLYZA® (saxagliptin) demonstrates no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial
2 September 2013 | By AstraZeneca
SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments...
Daiichi Sankyo’s once-daily edoxaban shows comparable efficacy and superiority for the principal safety endpoint compared to warfarin in a Phase 3 study for the treatment of symptomatic VTE and prevention of its recurrence
1 September 2013 | By Daiichi Sankyo
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...
Amgen presents pooled analysis showing AMG 145 significantly reduced LDL Cholesterol in over 1,200 patients
1 September 2013 | By Amgen
Results of analyses presented at ESC Congress 2013...
New Eliquis® (apixaban) post-hoc subanalysis of the Phase III ARISTOTLE trial demonstrated that within 30 days of a procedure, stroke or systemic embolism and major bleeding were uncommon
31 August 2013 | By Pfizer
Results presented at the ESC Congress 2013...
European Commission approves Genzyme’s once-daily, oral multiple sclerosis treatment Aubagio® (teriflunomide)
30 August 2013 | By Sanofi
Sanofi and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Aubagio® (teriflunomide)...
Teva reports top-line results from final Phase III study of armodafinil (NUVIGIL®) in patients with major depression associated with bipolar I disorder
30 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL®)...
Oral nutritional supplements in the hospital demonstrate significant health and cost benefits in new research
30 August 2013 | By Abbott
Analysis of more than 1 million adult hospital cases revealed 21 percent reduction in length of hospital stay and cost with nutritional intervention...
Daiichi Sankyo submits application to manufacture and market RANMARK® for treatment of giant cell tumor of bone in Japan
29 August 2013 | By Daiichi Sankyo
Daiichi Sankyo has filed an application for approval in Japan to manufacture and market RANMARK®...
